Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
McKinsey
McKesson
Merck
Colorcon

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ABEMACICLIB

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Abemaciclib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01394016 A Phase 1 Study of LY2835219 In Participants With Advanced Cancer Active, not recruiting Eli Lilly and Company Phase 1 2009-12-01 The purpose of this study is to determine a safe dose of LY2835219 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2835219 in this population. Efficacy measures will be used to assess the activity of LY2835219 in this population.
NCT01739309 Study of LY2835219 for Mantle Cell Lymphoma Active, not recruiting Eli Lilly and Company Phase 2 2013-03-01 The purpose of this study is to estimate the disease control rate with LY2835219 for relapsed or refractory mantle cell lymphoma.
NCT01913314 A Study of ^14C-LY2835219 in Healthy Participants Completed Eli Lilly and Company Phase 1 2013-08-01 This type of study is called a radiolabeled study. For this study, LY2835219 (study drug) has been specially prepared to contain radiolabeled carbon [14C]. [14C] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered. In addition, this study will also evaluate the safety and tolerability of a single dose of LY2835219 when given to healthy participants. Information about any side effects that may occur will also be collected. This study will last about 3 weeks for each participant, not including screening.
NCT02014129 A Study of LY2835219 in Japanese Participants With Advanced Cancer Active, not recruiting Eli Lilly and Company Phase 1 2013-12-01 The main purpose of this study is to evaluate safety and side effects of LY2835219 in Japanese participants with advanced cancer.
NCT02057133 A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread Recruiting Eli Lilly and Company Phase 1 2014-03-01 The main purpose of this study is to evaluate the safety of a study drug known as LY2835219 in combination with different therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, or LY3023414 plus fulvestrant) for breast cancer that has spread to other parts of the body.
NCT02059148 A Study of LY2835219 in Healthy Participants Completed Eli Lilly and Company Phase 1 2014-02-01 Participants in this study will receive 3 single oral doses of LY2835219 at least 14 days apart. One dose will be given with a standard meal, one dose with a high-fat meal and one dose without food. The study will evaluate the effects of the standard and high-fat meals on how much drug gets into the bloodstream. Side effects will be documented. This study is approximately 43 days, not including screening. Screening is required within 28 days prior to the start of the study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Abemaciclib

Condition Name

Condition Name for Abemaciclib
Intervention Trials
Breast Cancer 10
Metastatic Breast Cancer 7
Advanced Cancer 6
Healthy 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Abemaciclib
Intervention Trials
Breast Neoplasms 23
Neoplasms 10
Carcinoma, Non-Small-Cell Lung 7
Neoplasm Metastasis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Abemaciclib

Trials by Country

Trials by Country for Abemaciclib
Location Trials
United States 287
Spain 20
France 17
Korea, Republic of 12
Germany 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Abemaciclib
Location Trials
Texas 21
Massachusetts 19
New York 18
Tennessee 16
California 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Abemaciclib

Clinical Trial Phase

Clinical Trial Phase for Abemaciclib
Clinical Trial Phase Trials
Phase 4 2
Phase 3 5
Phase 2 35
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Abemaciclib
Clinical Trial Phase Trials
Not yet recruiting 31
Recruiting 27
Completed 8
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Abemaciclib

Sponsor Name

Sponsor Name for Abemaciclib
Sponsor Trials
Eli Lilly and Company 56
Dana-Farber Cancer Institute 6
National Cancer Institute (NCI) 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Abemaciclib
Sponsor Trials
Industry 66
Other 37
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Moodys
Mallinckrodt
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.